ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: BRCA 2 Gene sequence Published; CALGB To Mark 40th Anniversary

March 8, 1996

Study Tracks Lifestyle Factors For Cancer Burden In Blacks

October 26, 2001

NCAB Approves 8 Cancer Centers As Comprehensive

October 4, 1991

US Oncology Clarifies Role of Pharmacy Committee

January 24, 2003

Program Announcement Completes NCI switch To Control Research

April 16, 1982

Cancer Centers Branch To Be ‘More Proactive,’ Kimes Tells NCAB

January 12, 1990